According to new research published in The Lancet.

The vaccine was generally well tolerated. A complete of 647 severe adverse events were reported, 402 in the vaccine group and 245 in the placebo group. Relating to lead author Dr Maria Rosario Capeding from the study Institute for Tropical Medication in the Philippines: Our outcomes claim that vaccination with CYD-TDV can decrease the incidence of symptomatic dengue contamination by over fifty % and importantly reduced serious disease and hospitalisations.Outcomes were presented during an oral presentation today at the 15th Annual Scientific Periods of the American Culture of Nuclear Cardiology in Philadelphia, Pennsylvania throughout a session highlighting late-breaker data. Statistically, regadenoson was found to be not significantly different from placebo in causing a >15 percent reduction in FEV1 in patients with asthma or COPD . Additionally, the switch in FEV1 was not affected by baseline disease severity for either the asthma or the COPD subject matter organizations.